Journal
CANCER CELL
Volume 26, Issue 3, Pages 374-389Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2014.07.010
Keywords
-
Categories
Funding
- NIH [R01-CA158283]
- Jefferson Pilot award
- Young Thousand Talents Program of China
- UNC URC
- IBM
- program for Chang Jiang Scholars and the Innovative Research Team in University [IRT13049]
Ask authors/readers for more resources
Splicing dysregulation is one of the molecular hallmarks of cancer. However, the underlying molecular mechanisms remain poorly defined. Here we report that the splicing factor RBM4 suppresses proliferation and migration of various cancer cells by specifically controlling cancer-related splicing. Particularly, RBM4 regulates Bcl-x splicing to induce apoptosis, and coexpression of Bcl-xL partially reverses the RBM4-mediated tumor suppression. Moreover, RBM4 antagonizes an oncogenic splicing factor, SRSF1, to inhibit mTOR activation. Strikingly, RBM4 expression is decreased dramatically in cancer patients, and the RBM4 level correlates positively with improved survival. In addition to providing mechanistic insights of cancer-related splicing dysregulation, this study establishes RBM4 as a tumor suppressor with therapeutic potential and clinical values as a prognostic factor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available